EA202092844A1 - Анти-интерлейкин-17а антитело, фармацевтическая композиция и их применение - Google Patents
Анти-интерлейкин-17а антитело, фармацевтическая композиция и их применениеInfo
- Publication number
- EA202092844A1 EA202092844A1 EA202092844A EA202092844A EA202092844A1 EA 202092844 A1 EA202092844 A1 EA 202092844A1 EA 202092844 A EA202092844 A EA 202092844A EA 202092844 A EA202092844 A EA 202092844A EA 202092844 A1 EA202092844 A1 EA 202092844A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- seq
- amino acid
- acid sequences
- sequences shown
- monoclonal antibody
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 102000013691 Interleukin-17 Human genes 0.000 abstract 3
- 108050003558 Interleukin-17 Proteins 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rehabilitation Therapy (AREA)
- Mycology (AREA)
Abstract
Настоящее изобретение относится к области лечения аутоиммунных заболеваний и молекулярной иммунологии, а именно к анти-IL-17A антителу, содержащей его фармацевтической композиции и их применению. Более конкретно, настоящее изобретение относится к моноклональному антителу или его антигенсвязывающему фрагменту, в котором вариабельная область тяжелой цепи моноклонального антитела содержит HCDR1-HCDR3 с аминокислотными последовательностями, приведенными в SEQ ID NO: 31-33 соответственно, или HCDR1-HCDR3 с аминокислотными последовательностями, приведенными в SEQ ID NO: 37-39 соответственно, и вариабельная область легкой цепи моноклонального антитела содержит LCDR1-LCDR3 с аминокислотными последовательностями, приведенными в SEQ ID NO: 34-36 соответственно, или LCDR1-LCDR3 с аминокислотными последовательностями, приведенными в SEQ ID NO: 40-42 соответственно. Моноклональные антитела по настоящему изобретению могут специфически связываться с IL-17A, специфически противодействовать связыванию IL-17A с его лигандом и подавлять опосредованную IL-17A активацию фибробластов.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810539405.0A CN110551215A (zh) | 2018-05-30 | 2018-05-30 | 抗白细胞介素-17a抗体、其药物组合物及其用途 |
PCT/CN2019/088344 WO2019228266A1 (zh) | 2018-05-30 | 2019-05-24 | 抗白细胞介素-17a抗体、其药物组合物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202092844A1 true EA202092844A1 (ru) | 2021-03-16 |
Family
ID=68697430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202092844A EA202092844A1 (ru) | 2018-05-30 | 2019-05-24 | Анти-интерлейкин-17а антитело, фармацевтическая композиция и их применение |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210122815A1 (ru) |
EP (1) | EP3805264A4 (ru) |
JP (1) | JP2021526022A (ru) |
KR (1) | KR20210018336A (ru) |
CN (2) | CN110551215A (ru) |
AU (1) | AU2019276486A1 (ru) |
BR (1) | BR112020024512A2 (ru) |
CA (1) | CA3099530A1 (ru) |
EA (1) | EA202092844A1 (ru) |
IL (1) | IL279015B1 (ru) |
MX (1) | MX2020012847A (ru) |
PH (1) | PH12020551978A1 (ru) |
SG (1) | SG11202011262YA (ru) |
WO (1) | WO2019228266A1 (ru) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113024672B (zh) * | 2019-12-24 | 2022-05-31 | 深圳华大生命科学研究院 | 一种抗Dig的抗体及其在测序中的应用 |
CN114805577B (zh) * | 2019-12-31 | 2023-11-21 | 南京融捷康生物科技有限公司 | 针对il-17ra蛋白的抗体及其制备方法和应用 |
CN111690065B (zh) * | 2020-06-19 | 2021-04-02 | 北京东方百泰生物科技股份有限公司 | 一种抗il-17ra单克隆抗体的纯化方法 |
CN114057871B (zh) * | 2020-08-07 | 2023-08-01 | 沈阳何氏眼产业集团有限公司 | 抗人periostin单克隆嵌合抗体及应用 |
CN114276450B (zh) * | 2020-09-27 | 2023-08-29 | 江苏荃信生物医药股份有限公司 | 抗人il-17a单克隆抗体及其用途 |
CN112250764B (zh) * | 2020-10-22 | 2022-07-29 | 深圳市康瑞克生物科技有限责任公司 | 一种抗白细胞介素17a的单克隆抗体、其编码基因及应用 |
CN112300285B (zh) * | 2020-11-06 | 2022-08-02 | 江苏荃信生物医药股份有限公司 | 一种定量检测血清中抗人白介素17单克隆抗体含量的酶联免疫分析方法 |
CN114685668B (zh) * | 2020-12-28 | 2023-10-13 | 石药集团巨石生物制药有限公司 | 一种人gpc3单克隆抗体及其缀合物 |
CN115746132B (zh) * | 2021-09-03 | 2023-09-08 | 三优生物医药(上海)有限公司 | 抗il-17a抗体及其用途 |
CN113817058B (zh) * | 2021-09-30 | 2023-05-26 | 港科鹏禾生物(苏州)有限公司 | 一种抗人il-17rc的单克隆抗体及其应用 |
CN113896793B (zh) * | 2021-09-30 | 2023-05-26 | 港科鹏禾生物(苏州)有限公司 | 一种抗人il-17rc的单克隆抗体及其应用 |
WO2023060211A1 (en) * | 2021-10-06 | 2023-04-13 | The University Of Chicago | Borealin targeting polypeptides for detection and treatment of cancer |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US20110293629A1 (en) * | 2010-05-14 | 2011-12-01 | Bastid Jeremy | Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists |
WO2014001368A1 (en) * | 2012-06-25 | 2014-01-03 | Orega Biotech | Il-17 antagonist antibodies |
RU2577228C2 (ru) * | 2014-03-14 | 2016-03-10 | Закрытое Акционерное Общество "Биокад" | Анти-il-17-антитела, способ их получения и способ применения |
WO2016082193A1 (zh) * | 2014-11-28 | 2016-06-02 | 中国医学科学院药物研究所 | 全人源抗人白介素17a单链抗体 |
CN108251431B (zh) * | 2015-03-05 | 2020-12-08 | 北京百特美博生物科技有限公司 | 双载体系统及其用途 |
GB201522391D0 (en) * | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibody molecules |
CN107488227A (zh) * | 2016-06-12 | 2017-12-19 | 三生国健药业(上海)股份有限公司 | 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用 |
WO2017221174A1 (en) * | 2016-06-22 | 2017-12-28 | Novartis Ag | Methods of treating vitiligo using interleukin-17 (il-17) antibodies |
KR102329490B1 (ko) * | 2016-09-14 | 2021-11-23 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Il-17a에 특이적으로 결합하는 항체 및 그의 기능성 단편 |
-
2018
- 2018-05-30 CN CN201810539405.0A patent/CN110551215A/zh active Pending
-
2019
- 2019-05-24 EA EA202092844A patent/EA202092844A1/ru unknown
- 2019-05-24 BR BR112020024512-7A patent/BR112020024512A2/pt unknown
- 2019-05-24 EP EP19811445.6A patent/EP3805264A4/en active Pending
- 2019-05-24 CA CA3099530A patent/CA3099530A1/en active Pending
- 2019-05-24 AU AU2019276486A patent/AU2019276486A1/en active Pending
- 2019-05-24 CN CN201980036614.6A patent/CN112424224B/zh active Active
- 2019-05-24 US US17/055,252 patent/US20210122815A1/en active Pending
- 2019-05-24 IL IL279015A patent/IL279015B1/en unknown
- 2019-05-24 KR KR1020207037874A patent/KR20210018336A/ko unknown
- 2019-05-24 JP JP2020566731A patent/JP2021526022A/ja active Pending
- 2019-05-24 WO PCT/CN2019/088344 patent/WO2019228266A1/zh active Application Filing
- 2019-05-24 MX MX2020012847A patent/MX2020012847A/es unknown
- 2019-05-24 SG SG11202011262YA patent/SG11202011262YA/en unknown
-
2020
- 2020-11-19 PH PH12020551978A patent/PH12020551978A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PH12020551978A1 (en) | 2021-09-13 |
US20210122815A1 (en) | 2021-04-29 |
KR20210018336A (ko) | 2021-02-17 |
CN110551215A (zh) | 2019-12-10 |
BR112020024512A2 (pt) | 2021-03-02 |
MX2020012847A (es) | 2021-02-17 |
CN112424224A (zh) | 2021-02-26 |
EP3805264A1 (en) | 2021-04-14 |
WO2019228266A1 (zh) | 2019-12-05 |
IL279015A (en) | 2021-01-31 |
IL279015B1 (en) | 2024-05-01 |
CA3099530A1 (en) | 2019-12-05 |
SG11202011262YA (en) | 2020-12-30 |
CN112424224B (zh) | 2022-11-29 |
AU2019276486A1 (en) | 2020-11-26 |
EP3805264A4 (en) | 2022-05-18 |
JP2021526022A (ja) | 2021-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202092844A1 (ru) | Анти-интерлейкин-17а антитело, фармацевтическая композиция и их применение | |
CY1123212T1 (el) | Συνθεσεις για την αναστολη της ενεργοποιησης του masp-2 εξαρτωμενου συμπληρωματος | |
EA201990570A1 (ru) | Моноклональное антитело против pd1, его фармацевтическая композиция и их применение | |
RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
EA201591153A1 (ru) | Антитела, связывающиеся с tl1a, и их применение | |
EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
RU2013144392A (ru) | Антитела к рецептору il-6 и способы применения | |
AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
NZ589434A (en) | Dual variable domain immunoglobulins and uses thereof | |
RU2011140509A (ru) | Гетеродимерные полипептиды il-17a/f и возможности их лечебного применения | |
RU2531523C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
PE20190737A1 (es) | Anticuerpos anti-cd27 | |
GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
RU2011108260A (ru) | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей | |
EA201070888A1 (ru) | Антитела и их производные | |
RU2014100111A (ru) | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ | |
EA202090800A1 (ru) | Новые анти-cd3-эпсилон антитела | |
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
ZA202205288B (en) | Humanized antibody and method for using the same |